Reginster Jean-Yves, Collette Julien, Neuprez Audrey, Zegels Brigitte, Deroisy Rita, Bruyere Olivier
Bone. 2008 May;42(5):832-6. doi: 10.1016/j.bone.2008.01.021. Epub 2008 Feb 15.
Most of the currently available anti-osteoporosis medications promptly and significantly influence the rate of bone turnover. Biochemical markers of bone turnover now provide a high sensitivity to change, allowing the detection of these bone turnover changes within a couple of weeks. Since the anti-fracture efficacy of inhibitors of bone resorption or stimulators of bone formation appears to be largely independent of baseline bone turnover, biochemical markers do not appear to play a significant role in the selection of one particular drug, for an individual patient. However, there are consistent data showing that short-term changes in biochemical markers of bone turnover may be significant predictors of future changes in bone mineral density or fracture reduction, hence suggesting that bone turnover markers play a significant role in the monitoring of anti-osteoporosis therapy.
目前可用的大多数抗骨质疏松药物能迅速且显著地影响骨转换率。骨转换的生化标志物现在对变化具有高敏感性，能够在几周内检测到这些骨转换变化。由于骨吸收抑制剂或骨形成刺激剂的抗骨折疗效似乎在很大程度上独立于基线骨转换，对于个体患者而言，生化标志物在选择一种特定药物时似乎并不起重要作用。然而，有一致的数据表明，骨转换生化标志物的短期变化可能是未来骨矿物质密度变化或骨折减少的重要预测指标，因此提示骨转换标志物在抗骨质疏松治疗的监测中起重要作用。
